Leidenfrost Microdroplets for Rapid API Stability Analysis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional forced degradation methods for active pharmaceutical ingredients (APIs) are time-consuming, typically taking 1-7 days, which hinders the rapid assessment of degradation chemistry and stability, especially under hydrolysis and oxidation conditions.
Innovation Solution
The method employs Leidenfrost effect to create small levitated droplets as reaction vessels, accelerating chemical reactions by leveraging the large surface-to-volume ratio, allowing for faster degradation analysis of APIs under conditions like acid addition, base addition, or heat, and using techniques like mass spectrometry for rapid analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional forced degradation methods are used, then degradation chemistry can be assessed, but the process takes considerable time (1-7 days)
Solution Approach 1:
The patent divides the bulk reaction mixture into numerous small microdroplets (1-100 microliters each). This segmentation increases the total surface area to volume ratio, allowing faster heat and mass transfer. The API is distributed across many small reaction vessels (microdroplets) rather than one large vessel, enabling accelerated degradation while maintaining representative chemistry.
Solution Approach 2:
The patent changes the physical state and dimensions of the reaction vessels from bulk solution to microdroplets. This parameter change (size reduction) fundamentally alters the degradation kinetics by increasing surface area to volume ratio, enabling the same degradation chemistry to occur 10-100 times faster while maintaining analytical reliability.
2Productivity
If microdroplets are used to accelerate degradation, then degradation rate increases, but analysis of degradation products becomes more challenging
Solution Approach 1:
The patent combines multiple microdroplet reactions into a single collection vessel. After the accelerated degradation occurs in individual microdroplets, they are merged together to concentrate the degradation products, making them detectable and measurable by standard analytical techniques like HPLC or mass spectrometry.
Solution Approach 2:
The patent uses an intermediary collection vessel to receive and concentrate degradation products from multiple microdroplets. This intermediary step allows the fast microdroplet reactions to be coupled with slower, more sensitive bulk analysis methods, bridging the gap between speed and detection capability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach significantly accelerates the degradation process, achieving acceleration factors of 20 to 180 compared to traditional methods, enabling faster stability analysis and potential for scaled-up automated synthesis, while maintaining the reliability of degradation product characterization.
Implementation Method 1
Certain aspects of the invention employ the Leidenfrost effect to create small levitated droplets. By pouring a liquid onto a surface at a temperature significantly greater than the boiling point of the liquid, levitating solution droplets can be created from which solvent gradually evaporates.
Implementation Method 2
By pouring a liquid onto a surface at a temperature significantly greater than the boiling point of the liquid, levitating solution droplets can be created from which solvent gradually evaporates. These mm-sized droplets last for some minutes and when used as reaction vessels for APIs they force degradation to be even faster than would be the case under traditional forced degradation conditions
Data Source
AI summary
The invention generally relates to methods for analyzing stability of an active pharmaceutical agent. In certain aspects, the methods involve obtaining an active pharmaceutical agent, and distributing the active pharmaceutical agent into one or more microdroplets. The one or more microdroplets including the active pharmaceutical agent are then subjected to one or more conditions that force degradation of the active pharmaceutical agent in each of the one or more microdroplets. The one or more microdroplets are then analyzed to determine a ratio of the active pharmaceutical agent to that of a degradation product of the active pharmaceutical agent, thereby analyzing stability of an active pharmaceutical agent.